search
Back to results

Safety and Tolerability of BION-1301 in Healthy Volunteers and Adults With IgA Nephropathy (IgAN)

Primary Purpose

IgA Nephropathy

Status
Active
Phase
Phase 1
Locations
International
Study Type
Interventional
Intervention
BION-1301 Single Dose
Placebo Single Dose
BION-1301 Multiple Doses
Placebo Multiple Doses
Sponsored by
Chinook Therapeutics, Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for IgA Nephropathy

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria for Healthy Volunteers:

  1. Healthy male or female volunteers, 18 to 55 years old
  2. Females must be of non-childbearing potential
  3. Males must agree to follow the protocol-specified contraception guidance
  4. Body mass index (BMI) between 18 and 35 kg/m^2, with a weight of at least 50 kg
  5. Non-smoker, defined as an individual who has not smoked previously and/or who has discontinued smoking or the use of nicotine/nicotine-containing products at least 3 months before Screening
  6. Able to provide signed informed consent

Exclusion Criteria for Healthy Volunteers:

  1. Regular consumption of alcohol within 6 months prior to Screening, or use of soft drugs (such as marijuana) within 3 months prior to Screening, or hard drugs (such as cocaine and phencyclidine) within 1 year prior to Screening and/or positive blood or urine test results for drugs of abuse or alcohol at Screening or Admission
  2. Donated blood in the 3 months prior to the first dose of study drug, plasma in the 7 days prior to the first dose of study drug, or platelets in the 6 weeks prior to the first dose of study drug
  3. History or evidence of a clinically significant disorder, condition, or disease that could pose a risk to subject safety or interfere with the study, or would make the subject unsuitable for participation, eg, respiratory, renal, hepatic, gastrointestinal, hematological, lymphatic, neurological, cardiovascular, or psychiatric disease
  4. Female who is breastfeeding or who has a positive serum pregnancy test at Screening or a positive urine pregnancy test on Day -1

Inclusion Criteria for Adults with IgAN:

  1. Male or female ≥18 years old at Screening
  2. Women of child-bearing potential (WOCBP; per CTFG 2014) must agree to follow the protocol-specified contraception guidance throughout the study (from Screening through approximately 6 months after the final dose of study drug)
  3. Males must agree to follow the protocol-specified contraception guidance throughout the study (from Screening through approximately 6 months after the final dose of study drug)
  4. BMI between 18 and 40 kg/m^2, inclusive, at Screening with a weight of at least 50 kg
  5. Diagnosis of IgAN verified by biopsy taken within the past 10 years
  6. Urine protein ≥ 0.5 g/24h; OR UPCR ≥ 0.5 g/g (or ≥ 50 mg/mmol)
  7. eGFR (per Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI] formula) or measured GFR ≥ 30 mL/min per 1.73 m^2
  8. Stable on an optimized dose of angiotensin converting enzyme (ACE) inhibitors and/or angiotensin-receptor blockers (ARBs) for at least 3 months prior to Screening or intolerant to ACE/ARB

Exclusion Criteria for Adults with IgAN:

  1. Known or suspected allergy or hypersensitivity to any component of BION-1301, or history of severe hypersensitivity reaction to any monoclonal antibody
  2. Donated blood in the 3 months prior to the first dose of study drug; plasma in the 7 days prior to the first dose of study drug; or platelets in the 6 weeks prior to the first dose of study drug
  3. Participated in any other study in which receipt of an investigational new drug, or investigational device occurred within 28 days, or 5 half-lives (whichever is longer) of first dose of study drug in the present study
  4. Secondary forms of IgAN as defined by the treating physician (eg, Henoch-Schönlein purpura patients and those with associated alcoholic cirrhosis)
  5. Received systemic corticosteroid therapy (> 10 mg/day of prednisone or equivalent) or any other form of immunosuppressive therapy within 3 months prior to the first dose of study drug

Sites / Locations

  • National Institute of Clinical Research Phase One
  • Amicis Research Center
  • California Research Foundation
  • Nephrology Educational Services and Research
  • Colorado Kidney Care, P.C.
  • Elixia Tampa, LLC
  • Nephrology Associates of Central Florida
  • New York Nephrology
  • Chris Sholer, P.C.
  • Liberty Research Center
  • Liberty Research Center
  • Texas Research Institute
  • Prolato Clinical Research Center
  • Soon Chun Hyang University Hospital Cheonan
  • Hallym University Sacred Heart Hospital
  • National Health Insurance Service Ilsan Hospital
  • Hanyang University Guri Hostpital
  • Seoul National University Bundang Hospital
  • Liverpool University Hospital NHS Foundation Trust
  • PAREXEL Early Phase Clinical Unit

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm 5

Arm Type

Experimental

Placebo Comparator

Experimental

Placebo Comparator

Experimental

Arm Label

Part 1: BION-1301

Part 1: Placebo

Part 2: BION-1301

Part 2: Placebo

Part 3: BION-1301

Arm Description

Up to 5 cohorts with single ascending doses of BION-1301 administered by intravenous (IV) infusion.

Subjects will receive a single dose of placebo administered by IV infusion.

Up to 4 cohorts with multiple doses of BION-1301 administered by intravenous (IV) infusion.

Subjects will receive placebo by IV infusion.

Two cohorts of subjects will receive multiple doses of BION-1301 by IV infusion (Cohort 1) or SC injection (Cohort 2) at 600mg/biweekly.

Outcomes

Primary Outcome Measures

Incidence of Treatment Emergent Adverse Events (TEAEs) as assessed according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE)
Severity of TEAEs as assessed according to NCI-CTCAE

Secondary Outcome Measures

Full Information

First Posted
April 21, 2019
Last Updated
May 23, 2023
Sponsor
Chinook Therapeutics, Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT03945318
Brief Title
Safety and Tolerability of BION-1301 in Healthy Volunteers and Adults With IgA Nephropathy (IgAN)
Official Title
A Phase 1/2, Multicenter Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BION-1301 in Healthy Volunteers and Adults With IgA Nephropathy
Study Type
Interventional

2. Study Status

Record Verification Date
May 2023
Overall Recruitment Status
Active, not recruiting
Study Start Date
April 8, 2019 (Actual)
Primary Completion Date
November 2025 (Anticipated)
Study Completion Date
January 2026 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Chinook Therapeutics, Inc.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
Yes
Data Monitoring Committee
No

5. Study Description

Brief Summary
Multicenter study designed to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of BION-1301 in healthy volunteers and adults with IgA Nephropathy (IgAN).
Detailed Description
This is a Phase 1/2 study of BION-1301, a first-in-class humanized IgG4 anti-a proliferation-inducing ligand (APRIL) monoclonal antibody. The study will be conducted in three parts. Part 1: double-blind, randomized, placebo-controlled, single ascending dose (SAD) in healthy volunteers (HVs). Part 2: double-blind, randomized, placebo-controlled multiple ascending dose (MAD) in HVs. Part 3: Open-label, multiple dose (MD) in subjects with IgAN. Parts 1 and 2 have been completed. Part 3 enrollment is complete. The study will enroll up to 40 subjects with IgAN.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
IgA Nephropathy

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1, Phase 2
Interventional Study Model
Parallel Assignment
Model Description
Part 1 (SAD-HV) is a randomized, placebo-controlled single ascending dose design in HVs. Part 2 (MAD-HV): is a randomized, placebo-controlled multiple ascending dose design in HVs. Part 3 (MD-IgAN) is an open-label multiple dose design in subjects with IgAN.
Masking
ParticipantCare ProviderInvestigator
Masking Description
Parts 1 and 2 will be performed in a double-blind manner, for clinical research personnel interacting with study subjects. An unblinded pharmacist will prepare the doses of investigational study drugs.
Allocation
Randomized
Enrollment
103 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Part 1: BION-1301
Arm Type
Experimental
Arm Description
Up to 5 cohorts with single ascending doses of BION-1301 administered by intravenous (IV) infusion.
Arm Title
Part 1: Placebo
Arm Type
Placebo Comparator
Arm Description
Subjects will receive a single dose of placebo administered by IV infusion.
Arm Title
Part 2: BION-1301
Arm Type
Experimental
Arm Description
Up to 4 cohorts with multiple doses of BION-1301 administered by intravenous (IV) infusion.
Arm Title
Part 2: Placebo
Arm Type
Placebo Comparator
Arm Description
Subjects will receive placebo by IV infusion.
Arm Title
Part 3: BION-1301
Arm Type
Experimental
Arm Description
Two cohorts of subjects will receive multiple doses of BION-1301 by IV infusion (Cohort 1) or SC injection (Cohort 2) at 600mg/biweekly.
Intervention Type
Drug
Intervention Name(s)
BION-1301 Single Dose
Intervention Description
A solution for IV infusion administered as a single dose.
Intervention Type
Drug
Intervention Name(s)
Placebo Single Dose
Intervention Description
A solution by IV infusion administered as a single dose.
Intervention Type
Drug
Intervention Name(s)
BION-1301 Multiple Doses
Intervention Description
A solution for IV infusion or SC injections (Part 3 only) administered as multiple doses.
Intervention Type
Drug
Intervention Name(s)
Placebo Multiple Doses
Intervention Description
A solution by IV infusion administered as multiple doses.
Primary Outcome Measure Information:
Title
Incidence of Treatment Emergent Adverse Events (TEAEs) as assessed according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE)
Time Frame
Subjects followed from date of enrollment until the end of study, assessed up to 76 weeks.
Title
Severity of TEAEs as assessed according to NCI-CTCAE
Time Frame
Subjects followed from date of enrollment until the end of study, assessed up to 76 weeks.

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria for Healthy Volunteers: Healthy male or female volunteers, 18 to 55 years old Females must be of non-childbearing potential Males must agree to follow the protocol-specified contraception guidance Body mass index (BMI) between 18 and 35 kg/m^2, with a weight of at least 50 kg Non-smoker, defined as an individual who has not smoked previously and/or who has discontinued smoking or the use of nicotine/nicotine-containing products at least 3 months before Screening Able to provide signed informed consent Exclusion Criteria for Healthy Volunteers: Regular consumption of alcohol within 6 months prior to Screening, or use of soft drugs (such as marijuana) within 3 months prior to Screening, or hard drugs (such as cocaine and phencyclidine) within 1 year prior to Screening and/or positive blood or urine test results for drugs of abuse or alcohol at Screening or Admission Donated blood in the 3 months prior to the first dose of study drug, plasma in the 7 days prior to the first dose of study drug, or platelets in the 6 weeks prior to the first dose of study drug History or evidence of a clinically significant disorder, condition, or disease that could pose a risk to subject safety or interfere with the study, or would make the subject unsuitable for participation, eg, respiratory, renal, hepatic, gastrointestinal, hematological, lymphatic, neurological, cardiovascular, or psychiatric disease Female who is breastfeeding or who has a positive serum pregnancy test at Screening or a positive urine pregnancy test on Day -1 Inclusion Criteria for Adults with IgAN: Male or female ≥18 years old at Screening Women of child-bearing potential (WOCBP; per CTFG 2014) must agree to follow the protocol-specified contraception guidance throughout the study (from Screening through approximately 6 months after the final dose of study drug) Males must agree to follow the protocol-specified contraception guidance throughout the study (from Screening through approximately 6 months after the final dose of study drug) BMI between 18 and 40 kg/m^2, inclusive, at Screening with a weight of at least 50 kg Diagnosis of IgAN verified by biopsy taken within the past 10 years Urine protein ≥ 0.5 g/24h; OR UPCR ≥ 0.5 g/g (or ≥ 50 mg/mmol) eGFR (per Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI] formula) or measured GFR ≥ 30 mL/min per 1.73 m^2 Stable on an optimized dose of angiotensin converting enzyme (ACE) inhibitors and/or angiotensin-receptor blockers (ARBs) for at least 3 months prior to Screening or intolerant to ACE/ARB Exclusion Criteria for Adults with IgAN: Known or suspected allergy or hypersensitivity to any component of BION-1301, or history of severe hypersensitivity reaction to any monoclonal antibody Donated blood in the 3 months prior to the first dose of study drug; plasma in the 7 days prior to the first dose of study drug; or platelets in the 6 weeks prior to the first dose of study drug Participated in any other study in which receipt of an investigational new drug, or investigational device occurred within 28 days, or 5 half-lives (whichever is longer) of first dose of study drug in the present study Secondary forms of IgAN as defined by the treating physician (eg, Henoch-Schönlein purpura patients and those with associated alcoholic cirrhosis) Received systemic corticosteroid therapy (> 10 mg/day of prednisone or equivalent) or any other form of immunosuppressive therapy within 3 months prior to the first dose of study drug
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Charlotte Jones-Burton, M.D.
Organizational Affiliation
Chinook Therapeutics, Inc.
Official's Role
Study Director
Facility Information:
Facility Name
National Institute of Clinical Research Phase One
City
Garden Grove
State/Province
California
ZIP/Postal Code
92844
Country
United States
Facility Name
Amicis Research Center
City
Northridge
State/Province
California
ZIP/Postal Code
91324
Country
United States
Facility Name
California Research Foundation
City
San Diego
State/Province
California
ZIP/Postal Code
92123
Country
United States
Facility Name
Nephrology Educational Services and Research
City
Tarzana
State/Province
California
ZIP/Postal Code
91356
Country
United States
Facility Name
Colorado Kidney Care, P.C.
City
Denver
State/Province
Colorado
ZIP/Postal Code
80230
Country
United States
Facility Name
Elixia Tampa, LLC
City
Hollywood
State/Province
Florida
ZIP/Postal Code
33024
Country
United States
Facility Name
Nephrology Associates of Central Florida
City
Orlando
State/Province
Florida
ZIP/Postal Code
32806
Country
United States
Facility Name
New York Nephrology
City
Clifton Park
State/Province
New York
ZIP/Postal Code
12065
Country
United States
Facility Name
Chris Sholer, P.C.
City
Oklahoma City
State/Province
Oklahoma
ZIP/Postal Code
73116
Country
United States
Facility Name
Liberty Research Center
City
Arlington
State/Province
Texas
ZIP/Postal Code
76012
Country
United States
Facility Name
Liberty Research Center
City
Dallas
State/Province
Texas
ZIP/Postal Code
75230
Country
United States
Facility Name
Texas Research Institute
City
Fort Worth
State/Province
Texas
ZIP/Postal Code
76104
Country
United States
Facility Name
Prolato Clinical Research Center
City
Houston
State/Province
Texas
ZIP/Postal Code
77054
Country
United States
Facility Name
Soon Chun Hyang University Hospital Cheonan
City
Cheonan
State/Province
Chungcheongnamdo
ZIP/Postal Code
31151
Country
Korea, Republic of
Facility Name
Hallym University Sacred Heart Hospital
City
Anyang-si
State/Province
Gyeonggi-do
ZIP/Postal Code
14068
Country
Korea, Republic of
Facility Name
National Health Insurance Service Ilsan Hospital
City
Goyang-Si
State/Province
Gyeonggi-Do
ZIP/Postal Code
10444
Country
Korea, Republic of
Facility Name
Hanyang University Guri Hostpital
City
Guri-si
State/Province
Gyeonggi-do
ZIP/Postal Code
11923
Country
Korea, Republic of
Facility Name
Seoul National University Bundang Hospital
City
Seongnam-si
State/Province
Gyeonggi-do
ZIP/Postal Code
13620
Country
Korea, Republic of
Facility Name
Liverpool University Hospital NHS Foundation Trust
City
Liverpool
State/Province
England
ZIP/Postal Code
L7 8XP
Country
United Kingdom
Facility Name
PAREXEL Early Phase Clinical Unit
City
London
ZIP/Postal Code
HA1 3UJ
Country
United Kingdom

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Safety and Tolerability of BION-1301 in Healthy Volunteers and Adults With IgA Nephropathy (IgAN)

We'll reach out to this number within 24 hrs